MORGAN HILL, Calif. (PRWEB) November 10, 2017
Aragen Bioscience, Inc, a leading pre-clinical contract research organization specializing in the discovery and preclinical development of high-value biotech and pharmaceutical products, announced today full accreditation from the AAALAC (Association for Assessment and Accreditation of Laboratory Animal Care). “Animal research continues to play an important role in the development of novel and improved medicines to treat human diseases. We acknowledge that animal research is a subject of ethical concern for both our partners and the public; we take our responsibility to animal welfare very seriously,” commented Malavika Ghosh, Vice President, Preclinical Research. “We also recognize that laboratory animal research has proven to be an essential element in the development of therapeutics. As part of our commitment to the ethical and responsible treatment of animals in research, we have applied for and received full accreditation from AAALAC.” AAALAC accreditation is a voluntary, peer-reviewed assessment by a private nonprofit organization that promotes the humane treatment of animals in science. AAALAC accreditation is recognized worldwide as the “gold standard” for animal research programs.
“Our partners have come to rely on us for both the design and implementation of their preclinical studies," Dr. Ghosh continued, “AAALAC accreditation helps demonstrate that we are engaged in responsible animal research and dedicated to good science."
About Aragen Bioscience, Inc.
Aragen Bioscience, Inc., a wholly-owned subsidiary of GVK Bio, is a leading contract research organization based in the San Francisco Bay Area. Aragen Bioscience offers a diverse set of in vitro and in vivo services for the discovery, characterization, activity assessment and early development of biologic and diagnostic products. For additional information, please visit http://www.aragenbio.com.